We are upgrading the repository! A content freeze is in effect until December 11, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorXia, Xugang
dc.contributor.authorZhou, Hongxia
dc.contributor.authorDing, Hongliu
dc.contributor.authorAffar, El Bachir
dc.contributor.authorShi, Yang
dc.contributor.authorXu, Zuoshang
dc.date2022-08-11T08:09:35.000
dc.date.accessioned2022-08-23T16:36:45Z
dc.date.available2022-08-23T16:36:45Z
dc.date.issued2003-08-22
dc.date.submitted2009-04-02
dc.identifier.citationNucleic Acids Res. 2003 Sep 1;31(17):e100.
dc.identifier.issn1362-4962 (Electronic)
dc.identifier.pmid12930974
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38858
dc.description.abstractShort hairpin RNAs (shRNAs) transcribed by RNA polymerase III (Pol III) promoters can trigger sequence-selective gene silencing in culture and in vivo and, therefore, may be developed to treat diseases caused by dominant, gain-of-function type of gene mutations. These diseases develop in people bearing one mutant and one wild-type gene allele. While the mutant is toxic, the wild-type performs important functions. Thus, the ideal therapy must selectively silence the mutant but maintain the wild-type expression. To achieve this goal, we designed an shRNA that selectively silenced a mutant Cu,Zn superoxide dismutase (SOD1(G93A)) allele that causes amyotrophic lateral sclerosis. However, the efficacy of this shRNA was relatively modest. Since the allele-specific shRNA has to target the mutation site, we could not scan other regions of SOD1 mRNA to find the best silencer. To overcome this problem, we sought to increase the dose of this shRNA by enhancing the Pol III promoter. Here we demonstrate that the enhancer from the cytomegalovirus immediate-early promoter can enhance the U6 promoter activity, the synthesis of shRNA and the efficacy of RNA interference (RNAi). Thus, this enhanced U6 promoter is useful where limited choices of shRNA sequences preclude the selection of a highly efficient RNAi target region.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12930974&dopt=Abstract">Link to Article in PubMed</a>
dc.subjectBase Sequence
dc.subjectBlotting, Northern
dc.subjectBlotting, Western
dc.subjectCell Line
dc.subjectCytomegalovirus
dc.subjectEnhancer Elements (Genetics)
dc.subjectGene Expression Regulation, Enzymologic
dc.subjectGreen Fluorescent Proteins
dc.subjectHumans
dc.subjectLuminescent Proteins
dc.subjectMolecular Sequence Data
dc.subjectMutation
dc.subjectNucleic Acid Conformation
dc.subjectPromoter Regions (Genetics)
dc.subjectRNA Interference
dc.subjectRNA, Messenger
dc.subjectRNA, Small Interfering
dc.subjectRNA, Small Nuclear
dc.subjectSuperoxide Dismutase
dc.subjectTransfection
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleAn enhanced U6 promoter for synthesis of short hairpin RNA
dc.typeJournal Article
dc.source.journaltitleNucleic acids research
dc.source.volume31
dc.source.issue17
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2696&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1697
dc.identifier.contextkey808460
refterms.dateFOA2022-08-23T16:36:45Z
html.description.abstract<p>Short hairpin RNAs (shRNAs) transcribed by RNA polymerase III (Pol III) promoters can trigger sequence-selective gene silencing in culture and in vivo and, therefore, may be developed to treat diseases caused by dominant, gain-of-function type of gene mutations. These diseases develop in people bearing one mutant and one wild-type gene allele. While the mutant is toxic, the wild-type performs important functions. Thus, the ideal therapy must selectively silence the mutant but maintain the wild-type expression. To achieve this goal, we designed an shRNA that selectively silenced a mutant Cu,Zn superoxide dismutase (SOD1(G93A)) allele that causes amyotrophic lateral sclerosis. However, the efficacy of this shRNA was relatively modest. Since the allele-specific shRNA has to target the mutation site, we could not scan other regions of SOD1 mRNA to find the best silencer. To overcome this problem, we sought to increase the dose of this shRNA by enhancing the Pol III promoter. Here we demonstrate that the enhancer from the cytomegalovirus immediate-early promoter can enhance the U6 promoter activity, the synthesis of shRNA and the efficacy of RNA interference (RNAi). Thus, this enhanced U6 promoter is useful where limited choices of shRNA sequences preclude the selection of a highly efficient RNAi target region.</p>
dc.identifier.submissionpathoapubs/1697
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pagese100


Files in this item

Thumbnail
Name:
12930974.pdf
Size:
180.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record